{ "instance": { "lbph-20230630.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 552, "http://xbrl.sec.gov/dei/2022": 31 }, "contextCount": 144, "dts": { "calculationLink": { "local": [ "lbph-20230630_cal.xml" ] }, "definitionLink": { "local": [ "lbph-20230630_def.xml" ] }, "inline": { "local": [ "lbph-20230630.htm" ] }, "labelLink": { "local": [ "lbph-20230630_lab.xml" ] }, "presentationLink": { "local": [ "lbph-20230630_pre.xml" ] }, "schema": { "local": [ "lbph-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 413, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 3, "http://xbrl.sec.gov/dei/2022": 4, "total": 7 }, "keyCustom": 25, "keyStandard": 203, "memberCustom": 5, "memberStandard": 21, "nsprefix": "lbph", "nsuri": "http://www.longboardpharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Accrued Other Expenses", "menuCat": "Notes", "order": "10", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpenses", "shortName": "Accrued Other Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "11", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - License Agreement with Arena Pharmaceuticals, Inc.", "menuCat": "Notes", "order": "12", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsInc", "shortName": "License Agreement with Arena Pharmaceuticals, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "13", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Employment Benefits", "menuCat": "Notes", "order": "15", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureEmploymentBenefits", "shortName": "Employment Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "16", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "17", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Short-Term Investments (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsTables", "shortName": "Short-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Balance Sheets (unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "shortName": "Condensed Balance Sheets (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Accrued Other Expenses (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables", "shortName": "Accrued Other Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)", "menuCat": "Details", "order": "24", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "shortName": "Organization and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-5", "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "25", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "menuCat": "Details", "order": "26", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)", "menuCat": "Details", "order": "27", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "shortName": "Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Short-Term Investments - Summary of Short-Term Investments (Details)", "menuCat": "Details", "order": "28", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails", "shortName": "Short-Term Investments - Summary of Short-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)", "menuCat": "Details", "order": "29", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails", "shortName": "Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Balance Sheets (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_Securities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Short-Term Investments - Summary of Available-for-sale Investments (Details)", "menuCat": "Details", "order": "30", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "shortName": "Short-Term Investments - Summary of Available-for-sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_Securities", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Accrued Other Expenses - Summary of Accrued Other Expenses (Details)", "menuCat": "Details", "order": "31", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails", "shortName": "Accrued Other Expenses - Summary of Accrued Other Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Stockholders' Equity - Additional Information (Details)", "menuCat": "Details", "order": "32", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_2210918f-7dde-42ae-8d5b-c7640eddd63a", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_4a33976f-6a22-46e3-a76f-7cce44619527", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Stockholders' Equity - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)", "menuCat": "Details", "order": "33", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "shortName": "Stockholders' Equity - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "-3", "lang": null, "name": "us-gaap:PaymentsForFees", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "34", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_416eda80-91f2-4e21-ade2-dddf94f6e292", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "menuCat": "Details", "order": "35", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "2", "first": true, "lang": null, "name": "lbph:WeightedAverageStockPrice", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)", "menuCat": "Details", "order": "36", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions", "shortName": "Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "2", "first": true, "lang": null, "name": "lbph:WeightedAverageStockPrice", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)", "menuCat": "Details", "order": "37", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper", "shortName": "Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SecurityDeposit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "menuCat": "Details", "order": "38", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:LesseeOperatingLeaseDescription", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_779bd120-4cfe-472c-902a-4f6d3e40c4a8", "decimals": "0", "lang": null, "name": "lbph:AreaOfOfficeSpace", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "menuCat": "Details", "order": "39", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Statements of Operations and Comprehensive Loss (unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited", "shortName": "Condensed Statements of Operations and Comprehensive Loss (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_5d5ddcdc-1708-4fec-9a22-4bf1a987025f", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)", "menuCat": "Details", "order": "40", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "shortName": "Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)", "menuCat": "Details", "order": "41", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_b38d3d35-373b-43eb-9543-7e19863d1066", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Employment Benefits - Additional Information (Details)", "menuCat": "Details", "order": "42", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails", "shortName": "Employment Benefits - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Statements of Cash Flows (unaudited)", "menuCat": "Statements", "order": "5", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Organization and Basis of Presentation", "menuCat": "Notes", "order": "6", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "7", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "8", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Short-Term Investments", "menuCat": "Notes", "order": "9", "role": "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestments", "shortName": "Short-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lbph-20230630.htm", "contextRef": "C_8dfc50ae-d920-4bcf-ba31-61064de9cb62", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 28, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "lbph_AccruedComputerRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued computer related expenses", "label": "Accrued computer related expenses", "terseLabel": "Accrued computer related expenses" } } }, "localname": "AccruedComputerRelatedExpenses", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lbph_AccruedLegalAndAccountingFeesCurrent": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for legal and accounting fees received.", "label": "Accrued Legal and Accounting Fees, Current", "terseLabel": "Accrued legal and accounting fees" } } }, "localname": "AccruedLegalAndAccountingFeesCurrent", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lbph_AccruedRecruitmentFeesCurrent": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for recruitment fees received.", "label": "Accrued Recruitment Fees, Current", "terseLabel": "Accrued recruiting fees" } } }, "localname": "AccruedRecruitmentFeesCurrent", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lbph_AccruedResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses.", "label": "Accrued Research And Development Expenses", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpenses", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "lbph_AccruedTaxes": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Taxes", "label": "Accrued Taxes", "terseLabel": "Accrued taxes" } } }, "localname": "AccruedTaxes", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lbph_AccruedTravelExpenses": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued travel expenses", "label": "Accrued travel expenses", "terseLabel": "Accrued travel expenses" } } }, "localname": "AccruedTravelExpenses", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lbph_AreaOfOfficeSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of office space.", "label": "Area of Office Space", "terseLabel": "Area of office space" } } }, "localname": "AreaOfOfficeSpace", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "lbph_ArenaPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arena Pharmaceuticals, Inc.", "label": "Arena Pharmaceuticals Inc [Member]", "terseLabel": "Arena Pharmaceuticals, Inc." } } }, "localname": "ArenaPharmaceuticalsIncMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arena two thousand seventeen long term incentive plan.", "label": "Arena Two Thousand Seventeen Long Term Incentive Plan [Member]", "terseLabel": "Arena 2017 LTIP [Member]" } } }, "localname": "ArenaTwoThousandSeventeenLongTermIncentivePlanMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Three", "terseLabel": "Fixed maturity securities, available for sale, due after one year through three years, amortized cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three", "terseLabel": "Fixed maturity securities, available for sale, due after one year through three years, fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "lbph_DeferredFinancingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Financing Costs Policy Text Block", "label": "Deferred Financing Costs Policy [Text Block]", "terseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredFinancingCostsPolicyTextBlock", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "lbph_DefinedContributionPlanArenaMatchingContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan Arena Matching Contributions", "label": "Defined Contribution Plan Arena Matching Contributions", "terseLabel": "Matching contributions" } } }, "localname": "DefinedContributionPlanArenaMatchingContributions", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "lbph_EffectiveLeaseDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective lease date.", "label": "Effective Lease Date", "terseLabel": "Effective lease date" } } }, "localname": "EffectiveLeaseDate", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan, eligible earnings contribution, percentage.", "label": "Employee Stock Purchase Plan Eligible Earnings Contribution Percentage", "terseLabel": "Employee stock purchase plan, eligible earnings contribution, percentage" } } }, "localname": "EmployeeStockPurchasePlanEligibleEarningsContributionPercentage", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan, maximum offering period.", "label": "Employee Stock Purchase Plan Maximum Offering Period", "terseLabel": "Employee stock purchase plan, maximum offering period" } } }, "localname": "EmployeeStockPurchasePlanMaximumOfferingPeriod", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan, maximum shares purchased, value.", "label": "Employee Stock Purchase Plan Maximum Shares Purchased Value", "terseLabel": "Employee stock purchase plan, maximum shares purchased, value" } } }, "localname": "EmployeeStockPurchasePlanMaximumSharesPurchasedValue", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan, shares purchase price as a percentage of market fair value.", "label": "Employee Stock Purchase Plan Shares Purchase Price As Percentage Of Market Fair Value", "terseLabel": "Employee stock purchase plan, shares purchase price as a percentage of market fair value" } } }, "localname": "EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "lbph_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "follow on Public Offering.", "label": "Follow on Public Offering [Member]", "terseLabel": "Follow on Public Offering [Member]" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lbph_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of common stock.", "label": "Gross Proceeds From Issuance Of Common Stock", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses.", "label": "Increase Decrease In Accrued Research And Development Expenses", "negatedLabel": "Accrued research and development expenses" } } }, "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating right-of-use assets and lease liabilities, net.", "label": "Increase (Decrease) in Operating Right-Of-Use Assets and Lease Liabilities, Net", "terseLabel": "Operating right-of-use assets and lease liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "lbph_NonVotingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Voting Member.", "label": "Non Voting [Member]" } } }, "localname": "NonVotingMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lbph_NumberOfCommonStockSharesIssuedAndSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock Shares issued and sold.", "label": "Number of Common Stock Shares Issued and Sold" } } }, "localname": "NumberOfCommonStockSharesIssuedAndSold", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "lbph_OfferingCostsNotYetPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "offering costs not yet paid.", "label": "offering Costs not Yet Paid", "terseLabel": "Follow-on public offering costs in accrued other expenses" } } }, "localname": "OfferingCostsNotYetPaid", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "lbph_OptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase common stock [Member]", "label": "Options To Purchase Common Stock [Member]", "terseLabel": "Options To Purchase Common Stock" } } }, "localname": "OptionsToPurchaseCommonStockMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "lbph_PaymentsForRentHistorical": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Rent Historical", "label": "Payments For Rent Historical", "terseLabel": "Historical rent paid" } } }, "localname": "PaymentsForRentHistorical", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "lbph_PercentageOfIncreaseInRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in rent.", "label": "Percentage of Increase in Rent", "terseLabel": "Percentage of increase in rent by second year" } } }, "localname": "PercentageOfIncreaseInRent", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "lbph_PercentageOfSharesOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares of common stock outstanding", "label": "Percentage of shares of common stock outstanding", "terseLabel": "Percentage of shares of common stock outstanding" } } }, "localname": "PercentageOfSharesOfCommonStockOutstanding", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "lbph_PostSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Post split.", "label": "Post Split [Member]", "terseLabel": "Post Split" } } }, "localname": "PostSplitMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lbph_PreSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre split.", "label": "Pre Split [Member]", "terseLabel": "Pre Split" } } }, "localname": "PreSplitMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lbph_PropertyAndEquipmentInAccruedOtherExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property and equipment in accrued other expenses.", "label": "Property and Equipment in Accrued Other Expenses", "terseLabel": "Property and equipment in accrued other expenses" } } }, "localname": "PropertyAndEquipmentInAccruedOtherExpenses", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "lbph_RenewOfSuccessiveAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renew of successive agreement term.", "label": "Renew Of Successive Agreement Term", "terseLabel": "Renew of successive agreement term" } } }, "localname": "RenewOfSuccessiveAgreementTerm", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "lbph_RestrictedStockAwardsIssuedButUnvestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock awards, issued but unvested [Member]", "label": "Restricted Stock Awards Issued But Unvested [Member]", "terseLabel": "Restricted Stock Awards, Issued But Unvested" } } }, "localname": "RestrictedStockAwardsIssuedButUnvestedMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right-of-use assets obtained in exchange for lease obligations.", "label": "Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "lbph_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risks and Uncertainties Policy Text Block.", "label": "Risks And Uncertainties Policy [Text Block]", "terseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental balance sheet information related to leases.", "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]", "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases.", "label": "Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "lbph_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Preferred Stock (on an as-converted to common stock basis) [Member]", "label": "Series A Preferred Stock On As Converted To Common Stock Basis [Member]", "terseLabel": "Series A Preferred Stock On As Converted To Common Stock Basis" } } }, "localname": "SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options exercised in period, weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share based payment award, options forfeitures in period, weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remining Contractual Term, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining contractual term, options granted", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Contractual Term", "verboseLabel": "Remaining contractual term, options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining contractual term for option awards granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Remaining Contractual Term", "terseLabel": "Remaining Contractual Term, Options granted", "verboseLabel": "Remaining contractual term, options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options subject to early exercise provision, exercisable number", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Early Exercise Provision Exercisable Number", "terseLabel": "Options exercisable, subject to early exercise provision" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term (in Years) [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "lbph_ShortTermInvestmentsAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Short Term Investments And Cash Equivalents", "label": "Short Term Investments And Cash Equivalents", "terseLabel": "Short Term Investments And Cash Equivalents" } } }, "localname": "ShortTermInvestmentsAndCashEquivalents", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "lbph_ShortTermInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-Term Investments [Policy Text Block]", "label": "Short-Term Investments [Policy Text Block]", "terseLabel": "Short-Term Investments" } } }, "localname": "ShortTermInvestmentsPolicyTextBlock", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity and stockholders equity disclosure.", "label": "Temporary Equity And Stockholders Equity Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Equity Incentive Plan member.", "label": "Two Thousand And Twenty One Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lbph_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "lbph_VotingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting Member.", "label": "Voting [Member]" } } }, "localname": "VotingMember", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lbph_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate.", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted-average discount rate" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "lbph_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term.", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "lbph_WeightedAverageStockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average stock price", "label": "Weighted Average Stock Price", "terseLabel": "Stock price" } } }, "localname": "WeightedAverageStockPrice", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" ], "xbrltype": "perShareItemType" }, "lbph_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "Working Capital", "terseLabel": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.longboardpharma.com/20230630", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r237", "r238", "r239", "r240", "r270", "r422", "r437", "r468", "r469", "r478", "r482", "r490", "r529", "r565", "r566", "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]", "verboseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r237", "r238", "r239", "r240", "r270", "r422", "r437", "r468", "r469", "r478", "r482", "r490", "r529", "r565", "r566", "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProFormaMember": { "auth_ref": [ "r167", "r499", "r500" ], "lang": { "en-us": { "role": { "label": "Pro Forma [Member]", "terseLabel": "Pro Forma" } } }, "localname": "ProFormaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r237", "r238", "r239", "r240", "r263", "r270", "r298", "r299", "r300", "r398", "r422", "r437", "r468", "r469", "r478", "r482", "r490", "r525", "r529", "r566", "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r237", "r238", "r239", "r240", "r263", "r270", "r298", "r299", "r300", "r398", "r422", "r437", "r468", "r469", "r478", "r482", "r490", "r525", "r529", "r566", "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r167", "r271", "r499", "r516" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r167", "r271", "r499", "r500", "r516" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r518", "r561" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Other Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r489" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.", "label": "Accounts Payable, Related Parties, Noncurrent", "terseLabel": "Related party amounts related to accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r41" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "(Accretion) amortization of premiums on investments, net", "terseLabel": "Amortization of premiums on investments, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation and related expenses" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInsuranceCurrentAndNoncurrent": { "auth_ref": [ "r1", "r2", "r99", "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees.", "label": "Accrued Insurance", "terseLabel": "Insurance premium finance liability" } } }, "localname": "AccruedInsuranceCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued other expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued consulting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r23", "r24", "r135", "r434", "r445", "r449" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r21", "r24", "r88", "r385", "r440", "r441", "r507", "r508", "r509", "r513", "r514", "r515" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r7" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r307", "r308", "r309", "r513", "r514", "r515", "r558" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r122", "r123", "r124", "r125", "r126", "r155", "r156", "r157", "r158", "r167", "r200", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r307", "r308", "r309", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r363", "r364", "r366", "r367", "r368", "r369", "r380", "r381", "r382", "r383", "r384", "r385", "r424", "r425", "r426", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r85", "r86", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r110", "r131", "r150", "r187", "r195", "r197", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r325", "r329", "r348", "r489", "r527", "r528", "r563" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r128", "r136", "r150", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r325", "r329", "r348", "r489", "r527", "r528", "r563" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets", "totalLabel": "Total assets measured at fair value", "verboseLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r57" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r58" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses", "terseLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r203", "r225" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "More Than 12 months Losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Accumulated Loss", "terseLabel": "Unrealized Losses (Loss)" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Fair Value", "terseLabel": "Available-for-sale investments gross unrealized losses Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Less than 12 months Losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value", "terseLabel": "Available-for-sale investments gross unrealized losses Less than 12 months Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value", "terseLabel": "Available-for-sale investments gross unrealized Losses More than 12 months Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r60" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Fixed maturity securities, available for sale, due in one year or less, amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r59", "r204", "r432" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Fixed maturity securities, available for sale, due in one year or less, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r56", "r202", "r225", "r427" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Fixed maturity securities, available for sale, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BrokerageCommissionsRevenue": { "auth_ref": [ "r96", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commission revenue from buying and selling securities on behalf of customers.", "label": "Brokerage Commissions Revenue", "terseLabel": "Commissions" } } }, "localname": "BrokerageCommissionsRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r42", "r130", "r471" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r506" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents and investment securities", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]", "terseLabel": "Short-Term Investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r36", "r42", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r36", "r93" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "terseLabel": "Net (decrease) increase in cash and cash equivalents", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r132", "r133", "r134", "r150", "r170", "r171", "r173", "r175", "r179", "r180", "r213", "r241", "r243", "r244", "r245", "r248", "r249", "r253", "r254", "r255", "r256", "r259", "r348", "r470", "r498", "r511", "r517" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r16", "r104", "r115" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r64", "r235", "r236", "r465", "r526" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common Stock, Conversion Basis", "terseLabel": "Common stock, conversion basis" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockDiscountOnShares": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.", "label": "Common Stock, Discount on Shares", "terseLabel": "Discount and Commissions Paid" } } }, "localname": "CommonStockDiscountOnShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r513", "r514", "r558" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Voting Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total", "verboseLabel": "Common Stock Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r489" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r25", "r138", "r140", "r145", "r428", "r435" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive loss", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "verboseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r107", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r44", "r45", "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "negatedLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering", "negatedTerseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering", "terseLabel": "Conversion of convertible preferred stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r44", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "negatedLabel": "Conversion of non-voting common stock to voting common stock (in shares)", "negatedTerseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)", "terseLabel": "Number of Shares Converted", "verboseLabel": "Number of shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r44", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)", "verboseLabel": "Conversion of stock, shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r253", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r4", "r5", "r67", "r68", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Convertible preferred stock available for conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r479", "r481", "r573" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r211", "r230", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Available-for-sale Investments, More than 12 months, Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r211", "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "Available-for-sale Investments, More than 12 months, Unrealized Losses", "terseLabel": "Available-for-sale Investments, More than 12 months, Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Available-for-sale Investments, More than 12 months, Count" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r211", "r230", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Available-for-sale Investments, Less than 12 months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r211", "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Available-for-sale Investments, Less than 12 months, Unrealized Losses", "terseLabel": "Available-for-sale Investments, Less than 12 months, Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Available-for-sale Investments, Less than 12 months, Count" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r208", "r226", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Aggregate fair value of unrealized loss position", "totalLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Total", "verboseLabel": "Available-for-sale Investments, Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r209", "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "negatedLabel": "Available-for-sale Investments, Unrealized Losses", "terseLabel": "Available-for-sale Investments, Unrealized Losses", "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r207", "r475", "r524" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Available-for-sale Investments" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r210", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Available-for-sale Investments, Count" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r97", "r109", "r502" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred financing costs", "totalLabel": "Deferred Costs, Noncurrent, Total" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Company Provides Safe Harbor Contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r40", "r186" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r275", "r303", "r304", "r306", "r310", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r146", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r173", "r174", "r175", "r177", "r341", "r342", "r429", "r436", "r473" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic", "totalLabel": "Earnings Per Share, Basic, Total" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r146", "r159", "r160", "r161", "r162", "r163", "r170", "r173", "r174", "r175", "r177", "r341", "r342", "r429", "r436", "r473" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Convertible preferred stock:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r66", "r124", "r142", "r143", "r144", "r151", "r152", "r153", "r156", "r164", "r166", "r178", "r217", "r260", "r307", "r308", "r309", "r319", "r320", "r340", "r357", "r358", "r359", "r360", "r361", "r362", "r385", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r344", "r345", "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r250", "r264", "r265", "r266", "r267", "r268", "r269", "r345", "r395", "r396", "r397", "r476", "r477", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r250", "r264", "r269", "r345", "r395", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r250", "r264", "r269", "r345", "r396", "r476", "r477", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r250", "r264", "r265", "r266", "r267", "r268", "r269", "r345", "r397", "r476", "r477", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r250", "r264", "r265", "r266", "r267", "r268", "r269", "r395", "r396", "r397", "r476", "r477", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r205", "r206", "r220", "r221", "r222", "r223", "r224", "r229", "r231", "r232", "r252", "r258", "r331", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r475", "r519", "r520", "r521", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total", "verboseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r141", "r311", "r312", "r313", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r39" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r510" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued other expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedSalaries": { "auth_ref": [ "r39" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in accrued salaries.", "label": "Increase (Decrease) in Accrued Salaries", "negatedLabel": "Accrued compensation and related expenses", "terseLabel": "Accrued compensation and related expenses" } } }, "localname": "IncreaseDecreaseInAccruedSalaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r39" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r103", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Monthly interest expense" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of Maturity of the Short-Term Investments" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease expiry date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases, Operating [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee, Operating Lease, Description", "terseLabel": "Lease term, renew, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Commitments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r379" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r379" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r560" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r379" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "terseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r100", "r113", "r489", "r512", "r522", "r559" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r129", "r150", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r326", "r329", "r330", "r348", "r489", "r527", "r563", "r564" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r36", "r38", "r41" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r41", "r105", "r118", "r127", "r137", "r139", "r144", "r150", "r155", "r159", "r160", "r161", "r162", "r165", "r166", "r172", "r187", "r194", "r196", "r198", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r342", "r348", "r474", "r527" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r49", "r122", "r123", "r124", "r125", "r126", "r154", "r155", "r156", "r157", "r158", "r161", "r167", "r177", "r200", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r307", "r308", "r309", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r363", "r364", "r366", "r367", "r368", "r369", "r380", "r381", "r382", "r383", "r384", "r385", "r424", "r425", "r426", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonvotingCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors.", "label": "Nonvoting Common Stock [Member]", "terseLabel": "Non-Voting Common Stock [Member]" } } }, "localname": "NonvotingCommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r187", "r194", "r196", "r198", "r474" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r371" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease Liability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r371" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Right-of-use liabilities, current portion", "verboseLabel": "Right-of-use lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r371" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Right-of-use liabilities, net of current portion", "verboseLabel": "Right-of-use lease liabilities, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r372", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r370" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets", "verboseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r378", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r377", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Total rent expense", "totalLabel": "Operating Leases, Rent Expense, Net, Total" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other", "verboseLabel": "Accrued other expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r103", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other.", "label": "Other Employee-related Liabilities", "negatedLabel": "Total amount financed", "terseLabel": "Total amount financed" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestments": { "auth_ref": [ "r116", "r501" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term investments classified as other.", "label": "Other Long-Term Investments", "verboseLabel": "Other long-term assets" } } }, "localname": "OtherLongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other income (expense)" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOwnershipInterestsOfferingCosts": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of offering costs allocated to the other unit holders.", "label": "Other Ownership Interests, Offering Costs", "terseLabel": "Follow-on public offering costs in accrued other expenses" } } }, "localname": "OtherOwnershipInterestsOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PartnersCapitalAccountContributions": { "auth_ref": [ "r69", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).", "label": "Partners' Capital Account, Contributions", "terseLabel": "Arena Pharmaceuticals, Inc. capital contributions" } } }, "localname": "PartnersCapitalAccountContributions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Payments for Other Fees", "negatedLabel": "Financing related fees", "terseLabel": "Financing related fees" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Future rent payment per month for first year" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "auth_ref": [ "r33" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.", "label": "Payments for Repurchase of Initial Public Offering", "negatedLabel": "Follow-on public offering costs" } } }, "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r35" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Financing related fees", "totalLabel": "Payments of Financing Costs, Total" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Series A convertible preferred stock financing costs", "terseLabel": "Stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r31" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Purchases of short-term investments", "terseLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)", "terseLabel": "Expenses Related To Contribution Plan", "totalLabel": "Pension and Other Postretirement Benefits Cost (Reversal of Cost), Total" } } }, "localname": "PensionAndOtherPostretirementBenefitExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Postemployment Benefits [Abstract]" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.", "label": "Postemployment Benefits Disclosure [Text Block]", "terseLabel": "Employment Benefits" } } }, "localname": "PostemploymentBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureEmploymentBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The amount per share used to calculated dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount", "terseLabel": "Dividend rate, per-dollar-amount" } } }, "localname": "PreferredStockDividendRatePerDollarAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r253" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r253" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r489" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred Stock, Value, Issued", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r506" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r32" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from follow-on public offering", "verboseLabel": "Net Proceeds from Initial Public Offering(IPO)" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net Proceeds from Issuance" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r30", "r31" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "terseLabel": "Maturities of short-term investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r32", "r83" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r127", "r137", "r139", "r147", "r150", "r155", "r165", "r166", "r187", "r194", "r196", "r198", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r324", "r327", "r328", "r342", "r348", "r430", "r474", "r486", "r487", "r509", "r527" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r63", "r114", "r433", "r489" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment", "totalLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r63", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r120", "r388", "r389", "r562" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r386", "r387", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "License Agreement with Arena Pharmaceuticals, Inc." } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "terseLabel": "Payments of related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r87", "r119", "r571" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "R&D Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r70", "r112", "r444", "r449", "r489" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r124", "r151", "r152", "r153", "r156", "r164", "r166", "r217", "r307", "r308", "r309", "r319", "r320", "r340", "r440", "r442" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r376", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Public Offering Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Other Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary of Short-Term Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r81", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Company's Financial Assets Recognized at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.", "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]", "terseLabel": "Schedule of Services Expensed" } } }, "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureLicenseAgreementWithArenaPharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r272", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r76", "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted Average Grant Date Fair Values and Weighted Average Assumptions used to calculate Fair Value of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r503", "r504", "r530" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r39" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "verboseLabel": "Restricted stock award, Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock award, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock award, Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vesting of restricted stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Shares, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per share, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Number of Shares, Options cancelled", "terseLabel": "Number of Shares, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Shares, Options granted", "verboseLabel": "Number of shares, options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Estimated grant date fair value per share of award granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, Options outstanding, ending balance", "periodStartLabel": "Number of Shares, Options outstanding, beginning balance", "terseLabel": "Number of shares, options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per share, Options outstanding, ending balance", "periodStartLabel": "Weighted Average Exercise Price Per share, Options outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options exercisable, vested stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per share, Options vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per share, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per share, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per share, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Award expiration term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, Intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Number of Shares, Options Vested and Expected to Vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Price per share", "verboseLabel": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance , Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r101", "r102", "r108", "r505" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term Investments", "totalLabel": "Short-term Investments, Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r132", "r133", "r134", "r150", "r170", "r171", "r173", "r175", "r179", "r180", "r213", "r241", "r243", "r244", "r245", "r248", "r249", "r253", "r254", "r255", "r256", "r259", "r348", "r470", "r498", "r511", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r20", "r66", "r124", "r142", "r143", "r144", "r151", "r152", "r153", "r156", "r164", "r166", "r178", "r217", "r260", "r307", "r308", "r309", "r319", "r320", "r340", "r357", "r358", "r359", "r360", "r361", "r362", "r385", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r151", "r152", "r153", "r178", "r423" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r5", "r6", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Shares purchased" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r19", "r66", "r67", "r70", "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Stock issued during conversion of convertible securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r66", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in follow-on public offering (in shares)", "verboseLabel": "Share purchased" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the number of shares issued.", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "terseLabel": "Number of shares Exchanged During Period", "totalLabel": "Stock Issued During Period, Shares, Period Increase (Decrease), Total" } } }, "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r5", "r6", "r66", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Shares remained to vest", "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r66", "r70", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Shares, Options exercised", "terseLabel": "Exercise of stock options, shares", "verboseLabel": "Number of Shares, Options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r6", "r66", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in follow-on public offering", "verboseLabel": "Raised public offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r20", "r66", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options, value" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Common stock, subject to repurchase" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r55", "r489", "r512", "r522", "r559" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance, Value", "periodStartLabel": "Beginning Balance, Value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stockholders' Equity Note, Stock Split", "terseLabel": "Stock split, description" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Forward stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r17", "r150", "r213", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Temporary equity, Ending Balance, Value", "periodStartLabel": "Temporary equity, Beginning Balance, Value", "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Temporary Equity, Ending Balance, Shares", "periodStartLabel": "Temporary Equity, Beginning balance, Shares", "terseLabel": "Temporary equity, Balance (in shares)", "verboseLabel": "Temporary equity, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r205", "r206", "r252", "r258", "r331", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r519", "r520", "r521", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r122", "r123", "r124", "r125", "r126", "r155", "r156", "r157", "r158", "r167", "r200", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r307", "r308", "r309", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r363", "r364", "r366", "r367", "r368", "r369", "r380", "r381", "r382", "r383", "r384", "r385", "r424", "r425", "r426", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r472", "r479", "r572" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Government and agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfAvailableforsaleInvestmentsDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r431", "r479", "r573" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "Government and agency securities [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r40" ], "calculation": { "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Unrealized gain (loss) on short-term investments", "totalLabel": "Unrealized Gain (Loss) on Investments, Total", "verboseLabel": "Unrealized gain on short-term investments, net" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDetails", "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r52", "r53", "r54", "r181", "r182", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r169", "r175" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r168", "r175" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.longboardpharma.com/20230630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(a),(b))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r492": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r493": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r494": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r495": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r496": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r497": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-07)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "05", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941114&loc=d3e40544-110947", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }